[HTML][HTML] GLP-1 receptor agonists in the treatment of type 2 diabetes–state-of-the-art
MA Nauck, DR Quast, J Wefers, JJ Meier - Molecular metabolism, 2021 - Elsevier
Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …
type 2 diabetes in 2005 have been further developed to yield effective compounds …
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives
Executive summary 2020 will go down in history as the year when the global community was
awakened to the fragility of human health and the interdependence of the ecosystem …
awakened to the fragility of human health and the interdependence of the ecosystem …
Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine
Precision medicine is part of the logical evolution of contemporary evidence-based medicine
that seeks to reduce errors and optimize outcomes when making medical decisions and …
that seeks to reduce errors and optimize outcomes when making medical decisions and …
Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations
Nearly half of all adults with type 2 diabetes mellitus (T2DM) live in India and China. These
populations have an underlying predisposition to deficient insulin secretion, which has a key …
populations have an underlying predisposition to deficient insulin secretion, which has a key …
Polygenic risk scores for cardiovascular disease: a scientific statement from the American Heart Association
Cardiovascular disease is the leading contributor to years lost due to disability or premature
death among adults. Current efforts focus on risk prediction and risk factor mitigation ‚which …
death among adults. Current efforts focus on risk prediction and risk factor mitigation ‚which …
Pathophysiology-based subphenoty** of individuals at elevated risk for type 2 diabetes
The state of intermediate hyperglycemia is indicative of elevated risk of develo** type 2
diabetes. However, the current definition of prediabetes neither reflects subphenotypes of …
diabetes. However, the current definition of prediabetes neither reflects subphenotypes of …
Precision medicine in diabetes: a consensus report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
The convergence of advances in medical science, human biology, data science, and
technology has enabled the generation of new insights into the phenotype known as …
technology has enabled the generation of new insights into the phenotype known as …
100 years of insulin: celebrating the past, present and future of diabetes therapy
The year 2021 marks the centennial of Banting and Best's landmark description of the
discovery of insulin. This discovery and insulin's rapid clinical deployment effectively …
discovery of insulin. This discovery and insulin's rapid clinical deployment effectively …
Metabolic health and cardiometabolic risk clusters: implications for prediction, prevention, and treatment
Among 20 leading global risk factors for years of life lost in 2040, reference forecasts point to
three metabolic risks—high blood pressure, high BMI, and high fasting plasma glucose—as …
three metabolic risks—high blood pressure, high BMI, and high fasting plasma glucose—as …
Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes
Abstract Type 2 diabetes (T2D) is a complex chronic disease characterized by considerable
phenotypic heterogeneity. In this study, we applied a reverse graph embedding method to …
phenotypic heterogeneity. In this study, we applied a reverse graph embedding method to …